These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82. Inducible control of gene expression: prospects for gene therapy. Harvey DM; Caskey CT Curr Opin Chem Biol; 1998 Aug; 2(4):512-8. PubMed ID: 9736925 [TBL] [Abstract][Full Text] [Related]
83. Quantitative experiments on the mode of oestrogen-progesterone antagonism in the rabbit endometrium. HEATH G; HOHN EO; ROBSON JM J Physiol; 1952 Mar; 116(3):245-56. PubMed ID: 14939178 [No Abstract] [Full Text] [Related]
84. Long-term treatment with RU486 and glucocorticoid receptor resistance: theoretical and therapeutic implications. Lamberts SW; Koper JW; de Jong FH Trends Endocrinol Metab; 1992 Aug; 3(6):199-204. PubMed ID: 18407100 [TBL] [Abstract][Full Text] [Related]
85. Antagonism between progesterone and the synthetic oestrogenic substance, triphenyl ethylene. Robson JM J Physiol; 1938 May; 92(4):401-5. PubMed ID: 16994983 [No Abstract] [Full Text] [Related]
86. Progesterone influence on neurite outgrowth involves microglia. Wong AM; Rozovsky I; Arimoto JM; Du Y; Wei M; Morgan TE; Finch CE Endocrinology; 2009 Jan; 150(1):324-32. PubMed ID: 18772232 [TBL] [Abstract][Full Text] [Related]
87. Regulation of human endometrial function: mechanisms relevant to uterine bleeding. Critchley HO; Kelly RW; Baird DT; Brenner RM Reprod Biol Endocrinol; 2006; 4 Suppl 1(Suppl 1):S5. PubMed ID: 17118169 [TBL] [Abstract][Full Text] [Related]
88. Proven and potential clinical applications of mifpristone (RU486). Spitz IM Rev Endocr Metab Disord; 2002 Sep; 3(3):267-75. PubMed ID: 12215721 [No Abstract] [Full Text] [Related]
89. Antiprogestins: mechanism of action and contraceptive potential. Spitz IM; Croxatto HB; Robbins A Annu Rev Pharmacol Toxicol; 1996; 36():47-81. PubMed ID: 8725382 [TBL] [Abstract][Full Text] [Related]
90. Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms. Neulen J; Williams RF; Breckwoldt M; Chwalisz K; Baulieu EE; Hodgen GD Hum Reprod; 1996 Jul; 11(7):1533-7. PubMed ID: 8671500 [TBL] [Abstract][Full Text] [Related]
91. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Wolf JP; Hsiu JG; Anderson TL; Ulmann A; Baulieu EE; Hodgen GD Fertil Steril; 1989 Dec; 52(6):1055-60. PubMed ID: 2591563 [TBL] [Abstract][Full Text] [Related]
92. Oestrogen action in the endometrium and oviduct of rhesus monkeys during RU486 treatment. Brenner RM; Slayden OD Hum Reprod; 1994 Jun; 9 Suppl 1():82-97. PubMed ID: 7962475 [TBL] [Abstract][Full Text] [Related]
93. Endometrial effects of RU486 in primates--antiproliferative action despite signs of estrogen action and increased cyclin-B expression. Heikinheimo O; Hsiu JG; Gordon K; Kim S; Williams RF; Gibbons WE; Hodgen GD J Steroid Biochem Mol Biol; 1996 Oct; 59(2):179-90. PubMed ID: 9010333 [TBL] [Abstract][Full Text] [Related]
94. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hodgen GD; van Uem JF; Chillik CF; Danforth DR; Wolf JP; Neulen J; Williams RF; Chwalisz K Hum Reprod; 1994 Jun; 9 Suppl 1():77-81. PubMed ID: 7962474 [TBL] [Abstract][Full Text] [Related]